Table 3.
Rates of antimicrobial resistance among gram-positive bacteria most frequently isolated from patients with BSIs
| Microbiology | Antimicrobial drug nri/nrt(%resistant) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Penicillin | Ampicillin | Gentamicin | Erythomycin | Ciprofloxacin | Clindamycin | Linezolid | Vancomycin | Tetracycline | |
| staphylococcus | |||||||||
| Staphylococcus aureus | 96.2%(153/159) | 40.9%(65/159) | 32.7%(52/159) | 57.9%(92/159) | 34.6%(55/159) | 51.6%(82/159) | – | – | 30.8%(32/104) |
| CNS | 96.4%(429/445) | 74.4%(331/445) | 20.4%(91/445) | 85.6%(381/445) | 47.0%(209/445) | 69.2%(308/445 | – | – | * |
| staphylococcus epidermidis | 96.7%(731/756) | 88.0%(665/756) | 10.2%(77/756) | 85.1%(643/756) | 56.1%(424/756) | 45.2%(342/756) | – | 0.13%(1/756) | 2.2%(15/685) |
| MRSA | 100%(68/68) | 100%(68/68) | 47.1%(32/68) | 75.0%(51/68) | 86.8%(59/68) | 75.0%(51/68) | – | – | 38.2%(26/68) |
| Staphylococcus hominis | 91.0%(832/914) | 74.4%(680/914) | 2.7%(24/914) | 91.2%(834/914) | 52.6%(481/914) | 68.3%(624/914) | – | – | 42.8%(345/806) |
| Staphylococcus haemolyticus | 96.0%(117/122) | 94.3%(115/122) | 72.1%(88/122) | 95.1%(116/122) | 84.4%(103/122) | 52.5%(64/122) | – | – | 32.0%(39/122) |
| enterococcus | |||||||||
| E.faecalis | 9.1%(12/132) | 11.4%(15/132) | 31.1%(41/132) | 53.4%(31/58) | 35.6%(47/132) | * | 3.8%(5/132) | – | 59.5%(47/79) |
| E.faecium | 92.5%(272/294) | 91.5%(269/294) | 70.4%(207/294) | 74.3%(139/187) | 90.1%(265/294) | * | 3.1%(9/294) | 4.1%(12/294) | 43.8%(89/203) |
| Streptococcus | |||||||||
| Viri-dans streptococcus | 0%(0/32) | 0%(0/48) | * | 70.4%(23/24) | * | 0%(0/24) | 0%(0/25) | 0%(0/25) | * |
| Streptococcus pneumonia | 30%(3/10) | 80%(8/10) | * | 90%(9/10) | 0%(0/3) | 100%(1/1) | 0%(0/10) | 0%(0/10) | * |
nri number of resistant isolates, nrt number of isolates tested
-: without resistant; *: without test